BSE filing, NSE: CYIENT. Summary written from the filing by ALFA Finder's alert engine.
Cyient Ltd: key numbers
- Share price
- ₹1,108.30
- Market cap
- ₹12,315 Cr
- Revenue (annual)
- ₹7,268 Cr
- Net profit (annual)
- ₹427.9 Cr
- P/E (TTM)
- 33.1×Sector 23.6×
- Promoter holding
- 24.76%+1.48% QoQ
- FII holding
- 14.72%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cyient Ltd
All →Cyient Other Announcement
Cyient Ltd filed its quarterly shareholding pattern, showing promoter, institutional and public holdings. No transaction, capital event or promoter reclassification is disclosed.
Cyient Business Update
Cyient Semiconductors will exhibit at electronica 2026 in Munich, showcasing power management ICs and custom ASIC solutions. No new order or financial figure disclosed.
Cyient Earnings Call Transcript: Key Takeaways
Cyient delivered solid sequential growth led by robust performance in DET and DLM segments, bolstered by the integration of Thau Digital.
Cyient Acquisition Worth ₹0.01 Cr
Cyient Ltd will acquire the remaining 49% stake in subsidiary CSSPL for ₹0.01 Crore, making it a wholly-owned subsidiary.
- Value
- ₹0.01 Cr
- Execution
- 120 days
Cyient Results Update
Cyient reported its Q2 FY27 financial performance showing revenue and EBIT growth. The board also declared an interim dividend of ₹12 per share.
Cyient Employee Stock Options
Cyient Limited has announced the grant of 23,000 stock options and 26,400 restricted stock units to its associates.
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.